The prognostic value of BVAS and VDI in ANCA-AAV

The prognostic value of BVAS and VDI in ANCA-AAV

Dades bibliogràfiques
Autors principals:	Suppiah, R, Batra, R, Robson, J, Hoglund, P, Jayne, D, Westman, K, Luqmani, R
Format:	Conference item
Publicat:	2011

Ítems similars

THE PROGNOSTIC VALUE OF THE BIRMINGHAM VASCULITIS ACTIVITY SCORE AND THE VASCULITIS DAMAGE INDEX IN ANCA-ASSOCIATED VASCULITIS
per: Suppiah, R, et al.
Publicat: (2011)

Predicting cardiovascular events in patients with newly diagnosed ANCA-AAV
per: Suppiah, R, et al.
Publicat: (2011)

Birmingham Vasculitis Activity Score (BVAS) for use in European multi-centre clinical trials
per: Luqmani, R, et al.
Publicat: (2001)

Validation of the Birmingham Vasculitis Activity Score (BVAS) for use in European multi-centre clinical trials.
per: Luqmani, R, et al.
Publicat: (2000)

TREATMENT-RELATED DAMAGE IN THE ANCA-ASSOCIATED VASCULITIDES: AN ANALYSIS OF THE EUROPEAN VASCULITIS STUDY GROUP THERAPEUTIC TRIALS
per: Robson, J, et al.
Publicat: (2013)

Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials.
per: Robson, J, et al.
Publicat: (2015)

Damage in the ANCA-associated vasculitides: Long-term data from the European Vasculitis Study Group (EUVAS) therapeutic trials
per: Robson, J, et al.
Publicat: (2015)

Using the Birmingham vasculitis activity score (BVAS) to screen for vasculitis
per: Mukhtyar, C, et al.
Publicat: (2008)

Outcome measures in ANCA-associated vasculitis.
per: Suppiah, R, et al.
Publicat: (2010)

THE DEMOGRAPHY OF ANCA ASSOCIATED VASCULITIS: 735 PATIENTS RECRUITED AT DIAGNOSIS TO SIX EUROPEAN VASCULITIS STUDY GROUP TRIALS
per: Yew, S, et al.
Publicat: (2012)

Using the Birmingham Vasculitis Activity Score (BVAS) for diagnosing vasculitis
per: Luqmani, R, et al.
Publicat: (2009)

FACTORS ASSOCIATED WITH LONG-TERM DAMAGE IN THE ANCA-ASSOCIATED VASCULITIDES: AN ANALYSIS OF COHORTS FROM THE EUROPEAN VASCULITIS STUDY GROUP THERAPEUTIC TRIALS
per: Robson, J, et al.
Publicat: (2013)

Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.
per: Luqmani, R, et al.
Publicat: (1994)

THE VASCULITIS DAMAGE INDEX (VDI)
per: Exley, A, et al.
Publicat: (1995)

THE DISEASE CHARACTERISTICS OF ANCA ASSOCIATED VASCULITIS: 735 PATIENTS RECRUITED AT DIAGNOSIS TO SIX EUROPEAN VASCULITIS STUDY GROUP TRIALS
per: Yew, S, et al.
Publicat: (2012)

CONTEXTUALISING QUALITY OF LIFE IN ANCA ASSOCIATED VASCULITIS (AAV)
per: Basu, N, et al.
Publicat: (2012)

Cardiovascular outcomes in ANCA associated vasculitis
per: Mukhtyar, C, et al.
Publicat: (2008)

Determinants of Poor Quality of Life in ANCA Associated Vasculitis (AAV).
per: Basu, N, et al.
Publicat: (2012)

Modified Birmingham vasculitis activity score for Wegener's granulomatosis (BVAS/WG) - Construct validity.
per: Maiden, N, et al.
Publicat: (2000)

Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire
per: Robson, J, et al.
Publicat: (2018)

Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials.
per: Suppiah, R, et al.
Publicat: (2011)

Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials
per: Suppiah, R, et al.
Publicat: (2011)

Long-term survival of ANCA-associated vasculitis
per: Flossmann, O, et al.
Publicat: (2009)

MEASUREMENT OF DAMAGE IN SYSTEMIC VASCULITIS: A COMPARISON OF THE VASCULITIS DAMAGE INDEX (VDI) WITH THE COMBINED DAMAGE ASSESSMENT INDEX (CDA)
per: Suppiah, R, et al.
Publicat: (2010)

Cardiovascular outcomes in antineutrophil cytoplasm antibody associated vasculitis (AAV)
per: Mukhtyar, C, et al.
Publicat: (2008)

The UK & Ireland Vasculitis Registry (UKIVAS): Cross-sectional data on the first 2290 Patients with anti-neutrophil cytoplasm (ANCA) associated vasculitis (AAV)
per: Luqmani, R, et al.
Publicat: (2017)

Classification criteria for the anca-associated vasculitides
per: Robson, J, et al.
Publicat: (2019)

A four year analysis of variation in use of the anti-neutrophil cytoplasmic antibody (ANCA) test as a screening tool for ANCA-associated systemic vasculitis (AAV) in a teaching hospital.
per: McLaren, J, et al.
Publicat: (2000)

Long-term patient survival in ANCA-associated vasculitis
per: Flossmann, O, et al.
Publicat: (2011)

Long-term patient survival in ANCA-associated vasculitis.
per: Flossmann, O, et al.
Publicat: (2011)

Use of a computerised system to facilitate evaluation of anti-neutrophil cytoplasm (ANCA Associated) vasculitis (AAV) and other forms of systemic vasculitis
per: Luqmani, R, et al.
Publicat: (2017)

A disease-specific patient-reported outcome for ANCA associated vasculitis: scale structure and measurement properties of the AAV- PRO
per: Robson, J, et al.
Publicat: (2017)

Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): Part 2 - Treatment of eosinophilic granulomatosis with polyangiitis and diagnosis and general management of AAV
per: Sara Monti, et al.
Publicat: (2023-06-01)

SP0133 ANCA and their environment
per: Luqmani, R
Publicat: (2017)

Long-term patient survival in ANCA-associated vasculitis.
per: Flossmann, O, et al.
Publicat: (2011)

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
per: Jones, R, et al.
Publicat: (2010)

The role of rituximab in the treatment of ANCA-associated vasculitides (AAV)
per: Thomas Daikeler, et al.
Publicat: (2015-01-01)

A multi-centre randomised trial of cyclophosphamide versus azathioprine during remission in ANCA-associated systemic vasculitis (Cycazarem).
per: Luqmani, R, et al.
Publicat: (1999)

Diagnosis and management of ANCA associated vasculitis.
per: Berden, A, et al.
Publicat: (2012)

Glucocorticoid Treatment and Damage In The Antineutrophil- Cytoplasm Antibody Associated Vasculitides
per: Robson, J, et al.
Publicat: (2013)